43062T

8/9

for Early Stage Testicular Germ Cell Tumors：A Systematic Review. J Urol. 2020；203：894—901. 2） Fernandez EB, Colon E, McLeod DG, et al. Efficacy of radiographic chest imaging in patients with testicular cancer. Urology. 1994；44：243—8. 3） White PM, Adamson DJ, Howard GC, et al. Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol. 1999；54：207—11. 4） Horan G, Rafique A, Robson J, et al. CT of the chest can hinder the management of seminoma of the testis；it detects irrelevant abnormalities. Br J Cancer. 2007；96：882—5. 5） Yacoub JH, Oto A, Allen BC, et al. ACR Appropriateness Criteria Staging of Testicular Malignancy. J Am Coll Radiol. 2016；13：1203—9. 6） Gilligan T, Lin DW, Aggarwal R, et al. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019；17：1529—54. 7） Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and Treatment of Early Stage Testicular Can-cer：AUA Guideline. J Urol. 2019；202：272—81. 8） Honecker F, Aparicio J, Berney D, et al. ESMO Consensus Conference on testicular germ cell cancer：diagnosis, treatment and follow—up. Ann Oncol. 2018；29：1658—86. 9） Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer：2015 Update. Eur Urol. 2015；68：1054—68. 10） Hilton S, Herr HW, Teitcher JB, et al. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer：assessment of size and distribution criteria. AJR Am J Roentgenol. 1997；169：521—5. 11） Leibovitch L, Foster RS, Kopecky KK, et al. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol. 1995；154：1759—63. 12） de Wit M, Brenner W, Hartmann M, et al. ［18F］—FDG—PET in clinical stage Ⅰ／Ⅱ non—seminomatous germ cell tumours：results of the German multicentre trial. Ann Oncol. 2008；19：1619—23. 13） Sohaib SA, Koh DM, Barbachano Y, et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol. 2009；64：362—7. 14） Ambrosini V, Zucchini G, Nicolini S, et al. 18F—FDG PET／CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging. 2014；41：668—73. 15） Spermon JR, De Geus—Oei LF, Kiemeney LALM, et al. The role of（18）fluoro—2—deoxyglucose positron emission tomography in initial staging and re—staging after chemotherapy for testicular germ cell tumours. BJU Int. 2002；89：549—56. 16） Huddart RA, O’Doherty MJ, Padhani A, et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high—risk, clinical Stage Ⅰ nonseminomatous germ cell tumors. J Clin Oncol. 2007；25：3090—5. 17） Feldman DR, Lorch A, Kramar A, et al. Brain metastases in patients with germ cell tumors：prognos-tic factors and treatment options——an analysis from the Global Germ Cell Cancer Group. J Clin Oncol 2016；34：345—51. 18） Boyle HJ, Jouanneau E, Droz JP, et al. Management of brain metastases from germ cell tumors：a single center experience. Oncology. 2013；85：21—6.I．疫学・診断30